Corning Life Sciences to share suite of 3D cell culture technologies at SLAS2021
The new solutions support evolving industry needs such as COVID-19 response, disease models, and drug discovery
CORNING, N.Y. — Corning Incorporated (NYSE: GLW) will highlight its latest technologies that support the advancement of 3D cell culture, automation, and drug discovery at this year’s virtual Society for Laboratory Automation and Screening (SLAS) conference on Jan. 25 through 27.
Now more than ever, tools used to facilitate scale-up, reproducibility, and consistency of 3D cell culture are helping enable critical research needed to solve the industry’s most pressing problems.
Corning will share the newest products in its 3D cell culture portfolio, including Matrigel® matrix-3D plates, which can provide a more consistent, ready-to-use cell culture format to support organoid and spheroid culture models and reduce workflow steps. Also featured is Corning® Matrigel matrix for organoid culture, a vialed solution that is validated to support growth and differentiation of organoid culture and is also qualified to form stable “3D dome” structures commonly used in organoid culture.
New Corning Elplasia® plates, which will be highlighted at the conference, feature microcavity technology for high volume spheroid production, and Corning 3D clear tissue clearing reagent allows for rapid and easy imaging of 3D cultures. These new products are designed to address high throughput screening and imaging for 3D cell culture, while maintaining reproducibility and consistency – common barriers to widespread adoption of 3D workflows.
Corning Life Sciences experts – including John M. Tobin, vice president and general manager- will be available to discuss how these tools are being used to study and develop treatments for a variety of diseases and in other critical areas of research. Applications for these tools include drug screening, cancer and stem cell biology, 3D tissue engineering, immunology, immuno-oncology, and personalized medicine.
In addition, Corning will showcase its automation and disease modeling solutions used in diagnostic workflows, research and vaccine development, as well as efforts related to the COVID-19 response. These include lung organoids generated using Corning Matrigel matrix and air-liquid interface models produced with Transwell® and Falcon® permeable supports. The development of complex 3D models like these can aid in studying virus infectivity, helping to identify the best ways to treat and prevent disease. Other helpful tools, such as Corning robotic tips and assay microplates, are used in diagnostic workflows, and upstream solutions in bioproduction support vaccine development.
Corning and its customers will also offer several presentations during the virtual SLAS meeting including:
- Monday, Jan. 25, 2021
12:30 – 1 p.m. EST
Tutorial Session: “Gut-in-a-Dish” Model for Developing Personalized Therapies for Chronic Inflammatory Diseases
Presented by: Soumita Das, assistant professor, Dept. of Pathology, chief scientific director, HUMANOID, University of California San Diego
- Wednesday, Jan. 27, 2021
1:30 – 2 p.m. EST
Tutorial Session: High throughput Applications with Organoids
Presented by: Hilary Sherman, senior scientist, Corning Life Sciences
To learn more about how Corning is helping enable advancements in 3D cell culture with innovative technologies and workflow solutions, view the company’s digital booth #11 and schedule a virtual meeting with a member of the Corning executive team. Please contact:
Caution Concerning Forward-Looking Statements
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the duration and severity of the recent COVID-19 (coronavirus) outbreak, and its ultimate impact across our businesses on demand, operations and our global supply chains; the effects of acquisitions, dispositions and other similar transactions by the Company, the effect of global business, financial, economic and political conditions; tariffs and import duties; currency fluctuations between the U.S. dollar and other currencies, primarily the Japanese yen, New Taiwan dollar, euro, Chinese yuan, and South Korean won; product demand and industry capacity; competitive products and pricing; availability and costs of critical components and materials; new product development and commercialization; order activity and demand from major customers; the amount and timing of our cash flows and earnings and other conditions, which may affect our ability to pay our quarterly dividend at the planned level or to repurchase shares at planned levels; possible disruption in commercial activities due to terrorist activity, cyber-attack, armed conflict, political or financial instability, natural disasters, or major health concerns; unanticipated disruption to equipment, facilities, IT systems or operations; effect of regulatory and legal developments; ability to pace capital spending to anticipated levels of customer demand; rate of technology change; ability to enforce patents and protect intellectual property and trade secrets; adverse litigation; product and components performance issues; retention of key personnel; customer ability, most notably in the Display Technologies segment, to maintain profitable operations and obtain financing to fund their ongoing operations and manufacturing expansions and pay their receivables when due; loss of significant customers; changes in tax laws and regulations including the Tax Cuts and Jobs Act of 2017; and the potential impact of legislation, government regulations, and other government action and investigations.
For a complete listing of risks and other factors, please reference the risk factors and forward-looking statements described in our annual reports on Form 10-K and quarterly reports on Form 10-Q. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.
In accordance with guidance provided by the SEC regarding the use of company websites and social media channels to disclose material information, Corning Incorporated (“Corning”) wishes to notify investors, media, and other interested parties that it uses its website to publish important information about the company, including information that may be deemed material to investors, or supplemental to information contained in this or other press releases. The list of websites and social media channels that the company uses may be updated on Corning’s media and website from time to time. Corning encourages investors, media, and other interested parties to review the information Corning may publish through its website and social media channels as described above, in addition to the company’s SEC filings, press releases, conference calls, and webcasts.
About Corning Incorporated
Corning is one of the world’s leading innovators in materials science, with a 169-year track record of life-changing inventions. Corning applies its unparalleled expertise in glass science, ceramic science, and optical physics along with its deep manufacturing and engineering capabilities to develop category-defining products that transform industries and enhance people’s lives. Corning succeeds through sustained investment in RD&E, a unique combination of material and process innovation, and deep, trust-based relationships with customers who are global leaders in their industries. Corning’s capabilities are versatile and synergistic, which allows the company to evolve to meet changing market needs, while also helping our customers capture new opportunities in dynamic industries. Today, Corning’s markets include optical communications, mobile consumer electronics, display, automotive, and life sciences.
Corning Media Contact: